2025-01-30 12:01:00 :
Piramal Pharma LTD has a strong business in the inhaling anesthesia universal market in the United States and emerging markets Mint During the interview.
The company launched a hydrochloride hydrochloride hydrochloride hydrochloride for the treatment of mental illness on January 22. This is the latest injection of the Piramal intensive care unit of the complicated hospital of the company.
In 2024, it launched Edaravone injection for the treatment of muscle atrophic side cable sclerosis (ALS), and the new zinc sulfate zinc sulfate concentration for injection, and then the sodium and powerful sodium and powerful sodium sodium and strength of Pantoprazole sodium can be in 2023 Annual injection.
“Anesthetics and our injecting pain and in -sheath products will grow, but this is a general business. We already have a good market share, so we hope that these complex injection materials will be added to the investment portfolio. The development of the development project has also been developed and launched.
Complex hospital generic drugs
This pharmaceutical company reports that its complex hospital generic drug business increased by 14 % year -on -year in the third quarter, and the income was BleakThe 654 million rupees are mainly due to the strong sales in the inhaling anesthesia combination. The company is the largest seller in the US market. This is an inhaled anesthesia. It occupies more than 40 % of the market share in the US market and has a market share in the United States more than 70 % because the Baclofen in the sheath is a muscle relaxation agent Essence
According to the ICICI retail research report, SEVOFLURANE accounts for about 80 % of the global inhalation anesthesia market, because it has effect and quickly play a role, and exudes relatively few greenhouse gases. The paper states that it also has a faster appearance and recovery than other drugs.
A broker JM Financial said in a report last month that despite the pressure of pricing, the company’s hospital’s generic drug business and differentiated channels for differentiated channels have limited markets, which makes it a segment market segment that is profitable. , Its profit margin is 25-30 %. With the increase of production capacity and injection products in India’s Sevoflurane, the agent expects the market segment to increase by 11 % during the 24th fiscal year.
Piramal Pharma sold its domestic formula business to Abbott at a price of $ 3.8 billion in 2010. Subsequently, it strengthened its intensive care and generic drug business by mainly acquisition. The non -competitive agreement with Abbott expires in 2018.
American against wind
Piramal Pharma’s contract development and manufacturing (CDMO) business increased by 18 % year -on -year in the first nine months of fiscal year. This is the continuous traction of continuous commercial business manufacturing and general API business.
The company invested 80 million US dollars in the factory in Lexingdun, the United States last year, which will expand, which will be well attracted in the uncertainty of President Donald Trump’s future action.
“I don’t know what their plans are, so we must wait and see, but for those who want to make in the United States, we do have capacity, and we have a very powerful manufacturing network in the United States,” Piramal said.
Piramal expects that the CDMO business will be the company’s largest profit margin driving force in the near future, but in general, I hope [all businesses]Essence “
Piramal Pharma released its third quarter performance on Tuesday, with revenue increased by 12.54 % year -on -year Bleak2,204.22 million. Profit fell by 63.6 % Bleak3.68 million. EBITDA increased by 6 % year -on -year BleakThe EBITDA profit margin reported by the company was 16 %. The company estimates that by the 30th fiscal year, EBITDA’s profit margin will be 25 %, which will reach $ 2 billion in revenue.
Piramal Pharma’s stock price fell 0.25 % to Bleak239.10 at 11:28 am in BSE. In the past year, stocks have risen about 72 %.
Follow us On Social Media   Twitter/X